Recent development in melioidosis

Current Opinion in Infectious Diseases

Volumn 17, Issue 2, 2004, Pages 131-136

  Leelarasamee, Amorn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Burkholderia pseudomallei; Host pathogen relationship; Melioidosis; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT;

ALLELE; AMINO ACID SYNTHESIS; ANTIBODY RESPONSE; BACTERIAL MEMBRANE; BIOLOGICAL WARFARE; BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS; CELL KILLING; CLINICAL FEATURE; CLONE; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; MELIOIDOSIS; MORTALITY; NONHUMAN; RELAPSE; REVIEW; SEPTICEMIA; SERODIAGNOSIS; SURVIVAL; TRAVEL;

BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; HUMANS; MELIOIDOSIS;

EID: 1842609845     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200404000-00011     Document Type: Review

References (59)

1. Dance DA. Melioidosis. Curr Opin Infect Dis 2002; 15:127-132. A review of recent developments in melioidisis.
2. Leelarasamee A, Bovornkitti S. Melioidosis - an infection hazard to travelers visiting endemic areas. Intern Med J Thai 2001; 17:85-87.
3. Yazdanpanah Y, Lemaire X, Senneville E, et al. Melioidotic osteomyelitis of the femur occurring in a traveler. J Travel Med 2002; 9:53-54.
4. Heyse AM, Dierick J, Vanhouteghem H, et al. A case of imported melioidosis presenting as prostatitis. Infection 2003; 31:60-62.
5. Kanungo R, Padhan P, Bhattacharya S, et al. Melioidosis - a report from Pondicherry, South India. J Assoc Physicians India 2002; 50:1438-1439.
6. Heyse AM, Dierick J, Vanhouteghem H, et al. A case of imported melioidosis presenting as prostatitis. Infection 2003; 31:60-62.
7. John GT, Ahmed I, Jacob CK, et al. Melioidosis in a renal transplant recipient. Transplantation 2003; 76:262.
8. Cheng AC, Hanna JM, Norton R, et al. Melioidosis in northern Australia, 2001-02. Communic Dis Intell 2003; 27:272-277.
9. Faa AG, Holt PJ. Melioidosis in lhe Torres Strait islands of far North Queensland. Communic Dis Intell 2002; 26:279-283.
10. Leelarasamee A, Trakulsomboon S, Kusum M, Dejsirilert S. Isolation rates of Burkholderia pseudomallei among the four regions in Thailand. Southeast Asian J Trop Med Pub Health 1997; 28:107-113.
11. White NJ. Melioidosis. Lancet 2003; 361:1715-1722. A thorough review of various aspects of melioidosis.
12. Simpson AJ, Newton PN, Chierakul W, et al. Diabetes mellitus, insulin, and melioidosis in Thailand. Clin Infect Dis 2003; 36:71-72.
13. Chen YS, Chen SC, Kao CM, Chen YL. Effects of soil pH, temperature and water content on the growth of Burkholderia pseudomallei. Folia Microbiol (Praha) 2003; 48:253-256. Optimum conditions were determined for the growth of B. pseudomallei in natural soils or waters.
14. Godoy D, Randle G, Simpson AJ, et al. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2003; 41:2068-2079. This study showed similarity of the alleles of B. pseudomallei and B. mallei and confirmed that B. thailandensis is the separated specie by multilocus sequence typing.
15. Sonthayanon P, Krasao P, Wuthiekanun V, et al. A simple method to detect and differentiate Burkholderia pseudomallei and Burkholderia thailandensis using specific flagellin gene primers. Mol Cell Probes 2002; 16:217-222. Specific flagellin gene primers were used in a PCR-based method successfully to detect and distinguish B. pseudomallei and B. thailandensis in mixed culture and environmental situations.
16. Anuntagool N, Sirisinha S. Antigenic relatedness between Burkholderia pseudomallei and Burkholderia mallei. Microbiol Immunol 2002; 46:143-150.
17. Gee JE, Sacchi CT, Glass MB, et al. Use of 16S rRNA sequencing for rapid identification and differentiation of Burkholderia pseudomallei and B. mallei. J Clin Microbiol 2003; 41:4647-4654.
18. Inglis TJ, O'Reilly L, Foster N, et al. Comparison of rapid, automated ribotyping and DNA macrorestriction analysis of Burkholderia pseudomallei. J Clin Microbiol 2002; 40:3198-3203.
19. Smith-Vaughan HC, Gal D, Lawrie PM, et al. Ubiquity of putative type III secretion genes among clinical and environmental Burkholderia pseudomallei isolates in Northern Australia. J Clin Microbiol 2003; 41:883-885.
20. Chua KL, Chan YY, Gan YH. Flagella are virulence determinants of Burkholderia pseudomallei. Infect Immun 2003; 71:1622-1629. Flagella were shown to be important virulence determinants of B. pseudomallei during intranasal and intraperitoneal infection of mice.
21. Popov SF, Tikhonov NG, Piven' NN, et al. Immunobiological properties of Burkholderia pseuodomallei and Burkholderia mallei capsular substances. Zh Mikrobiol Epidemiol Immunobiol 2002; 6:60-64.
22. Atkins T, Prior R, Mack K, at al. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol 2002; 51:539-547. An acapsular mutant was found to be less virulent and failed to induce a protective immune response in a murine model.
23. Atkins T, Prior RG, Mack K, et al. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun 2002; 70:5290-5294. This study nicely delineated the mechanism of attenuation in a mutant and specific protection against challenge with the wild type of B. pseudomallei in a mouse model.
24. Segal BH, Ding L, Holland SM. Phagocyte NADPH oxidase, but not inducible nitric oxide synthase, is essential for early control of Burkholderia cepacia and Chromobacterium violaceum infection in mice. Infect Immun 2003; 71:205-210.
25. Utaisincharoen P, Anuntagool N, Limposuwan K, et al. Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages. Infect Immun 2003; 71:3053-3057. This study delineated one mechanism of intracellular survival of B. pseudomallei.
26. Utaisincharoen P, Kespichayawattana W, Anuntagool N, et al. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol 2003; 132:70-75.
27. Stevens MP, Wood MW, Taylor LA, et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 2002; 46:649-659. This study reports the finding of an Inv/Mxi-Spa-like type III protein secretion system that explains the intracellular survival and intercellular spread of B. pseudomallei.
28. Ketheesan N, Barnes JL, Ulett GC, et al. Demonstration of a cell-mediated immune response in melioidosis. J Infect Dis 2002; 186:286-289.
29. Vasu C, Vadivelu J, Puthucheary SD. The humoral immune response in melioidosis patients during therapy. Infection 2003; 31:24-30.
30. Liu B, Koo GC, Yap EH, et al. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun 2002; 70:504-511.
31. Jones SM, Ellis JF, Russell P, et al. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 2002; 51:1055-1062.
32. Ward C, Camara M, Forrest I, et al. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 2003; 58:444-446.
33. Tan JK, Yip SK, Png DJ, Moorthy P. Primary melioidotic prostatic abscess: presentation, diagnosis and management. Aust NZ J Surg 2002; 72:408-410.
34. Kiertiburanakul S, Sungkanuparph S, Kositchiwat S, Vorachit M. Burkholderia pseudomallei: abscess in an unusual site. J Postgrad Med 2002; 48:124-126.
35. Kosuwon W, Taimglang T, Sirichativapee W, Jeeravipoolvam P. Melioidotic septic arthritis and its risk factors. J Bone Joint Surg (Am Vol) 2003; 85A: 1058-1061.
36. Srirompotong S, Reechaipichitkul W. Disseminated septicaemic melioidosis: an unusual presentation of masticator space infection. J Laryngol Otol 2003; 117:417-418.
37. Tran D, Tan HH. Cutaneous melioidosis. Clin Exp Dermatol 2002; 27:280-282.
38. Luo CY, Ko WC, Lee HC, Yang YJ. Relapsing melioidosis as cause of iliac mycotic aneurysm: an indigenous case in Taiwan. J Vasc Surg 2003; 37:882-885.
39. Schindler N, Calligaro KD, Dougherty MJ, et al. Melioidosis presenting as an infected intrathoracic subclavian artery pseudoaneurysm treated with femoral vein interposition graft. J Vasc Surg 2002; 35:569-572.
40. Leelarasamee A, Bovornkitti S. Review. Infect Dis 1989; 11:413-425.
41. Wuthiekanun V, Suputtamongkol Y, Simpson AJ, et al. Value of throat swab in diagnosis of melioidosis. J Clin Microbiol 2001; 39:3801-3802.
42. Howard K, Inglis TJ. Novel selective medium for isolation of Burkholderia pseudomallei. J Clin Microbiol 2003; 41:3312-3316. This study reports a new selective agar that may be used instead of Ashdown selective media.
43. Lowe P, Engler C, Norton R. Comparison of automated and non-automated systems for identification of Burkholderia pseudomallei. J Clin Microbiol 2002; 40:4625-4627.
44. Woo PC, Woo GK, Lau SK, et al. Single gene target bacterial identification. groEL gene sequencing for discrimating clinical isolates of Burkholderia pseudomallei and Burkholderia thailandensis. Diagn Microbiol Infect Dis 2002; 44:143-149.
45. Woo PC, Lau SK, Woo GK, et al. Seronegative bacteremic melioidosis caused by Burkholderia pseudomallei with ambiguous biochemical profile: clinical importance of accurate identification by 16S rRNA gene and groEL gene sequencing. J Clin Microbiol 2003; 41:3973-3977. An unusual isolate of B. pseudomallei was identified by an automated system and the patient's acute and convalescent sera were non-reactive against the conventional lipopolysaccharide of B. pseudomallei in the ELISA test. Its phenotypic characteristics and the sequencing of the 16S rRNA gene and groEL gene showed that the isolate was B. pseudomallei.
46. Chen YS, Shiuan D, Chen SC, et al. Recombinant truncated flagellin of Burkholderia pseudomallei as a molecular probe for diagnosis of melioidosis. Clin Diagn Lab Immunol 2003; 10:423-425. This study showed that truncated flagellins were more sensitive and specific than full-length flagellins in an indirect ELISA, and achieved 93.8% sensitivity and 96.3% specificity.
47. Hagen RM, Gauthier YP, Sprague LD, et al. Strategies for PCR based detection of Burkholderia pseudomallei DNA in paraffin wax embedded tissues. Mol Pathol 2002; 55:398-400.
48. Ulett GC, Hirst R, Bowden B, et al. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J Antimicrob Chemother 2003; 51:77-81.
49. Cheung TK, Ho PL, Woo PC, et al. Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei. Antimicrob Agents Chemother 2002; 46:1132-1135.
50. Tribuddharat C, Moore RA, Baker P, Woods DE. Burkholderia pseudomallei class A beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob Agents Chemother 2003; 47:2082-2087.
51. Niumsup P, Wuthiekanum V. Cloning of the class D β-lactamase gene from the Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J Antimicrob Chemother 2002; 50:445-455. This study showed the ability of B. pseudomallei to yield mutants that overexpress β-lactamases and a detailed description of a class D β-lactamase gene.
52. Ho PL, Cheung TK, Kinoshita R, et al. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. J Antimicrob Chemother 2002; 49:1042-1044.
53. Minassian MA, Gage A, Price E, Sefton AM. Imipenem for the treatment of melioidoeis. Int J Antimicrob Agents 1999; 12:263-265.
54. Powell K, Ulett G, Hirst R, Norton R. G-CSF immunotherapy for treatment of acute disseminated murine melioidosis. FEMS Microbiol Lett 2003; 224:315-318.
55. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32:143-148.
56. Warawa J, Woods DE. Meliodiosis vaccines. Expert Rev Vaccines 2002; 1:477-482. A thorough review of the approaches and current strategies towards the development of vaccines against melioidosis.
57. Gan YH, Chua KL, Chua HH, et al. Characterization of Burkholderia pseudomallei infection and identification of novel virulence factors using a Caenorhabditis elegans host system. Mol Microbiol 2002; 44:1185-1197.
58. Woods DE. The use of animal infection models to study the pathogenesis of melioidosis and glanders. Trends Microbiol 2002; 10:483-484.
59. Jeddeloh JA, Fritz DL, Waag DM, et al. Biodefense-driven murine model of pneumonic melioidosis. Infect Immun 2003; 71:584-587.